Shokei Kim-Mitsuyama, M.D. Ph.D.
Primary tabs
JAD profile
Affiliation(s):
Kumamoto University Graduate School of Medical Sciences
Areas of Interest:
pathophysiology and novel therapeutics of Alzheimer’s disease, vascular cognitive impairment and stroke, clinical pharmacology, pathophysiology of metabolic syndrome and cardiovascular and renal diseases, the pathophysiological role of renin-angiotensin system.
Biography & Research:
Shokei Kim-Mitsuyama received his MD degree from the Osaka City University Medical School in 1982, and his PhD degree from the Osaka City University Graduate School of Medical Sciences in 1987. Upon completion of a medical internship and residency, he matriculated in the Department of Pharmacology, Osaka City University Medical School as a Research Associate, and was appointed Associate Professor of the department in 2001. He also worked for the Life Science Center of Tsukuba Advanced Research Alliance, University of Tsukuba, as a guest associate professor from 1997 to 1999. Since 2004, he has been Chairman and Professor of the Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan. He has been also a Guest Professor of Osaka City University Medical School from 2004 to 2013. He served as a Board Member of the Japanese Circulation Society, a Board Member of the Japanese Society of Hypertension, Editor-in-Chief of Hypertension Research, Editor of Journal of Pharmacological Sciences. He has held a Board Member of Japan Society of Circulation Control in Medicine and a Board Member of Japanese Society of Vascular Cognitive Impairment, Councilor of many scientific societies, and Editorial Board Member of Cardiovascular Diabetology, Circulation Journal, etc. He has been a Fellow of the American Heart Association and a Fellow of European Society of Cardiology. His research interests are pathophysiology and novel therapeutics of Alzheimer’s disease, vascular cognitive impairment and stroke, clinical pharmacology, pathophysiology of metabolic syndrome and cardiovascular and renal diseases, the pathophysiological role of renin-angiotensin system.
